Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters

Analytical Biochemistry

Volumn 437, Issue 1, 2013, Pages 77-87

  Strouse, J Jacob ^a,b,c   Ivnitski Steele, Irena ^a,b,c   Waller, Anna ^a,b,c   Young, Susan M ^a,b,c   Perez, Dominique ^a,b,c   Evangelisti, Annette M ^a,b,c   Ursu, Oleg ^b   Bologa, Cristian G ^b,c   Carter, Mark B ^a,b,c   Salas, Virginia M ^a,b,c   Tegos, George ^b   Larson, Richard S ^b   Oprea, Tudor I ^b   Edwards, Bruce S ^a,b,c   Sklar, Larry A ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

ABCB1; ABCC1; ABCG2; Efflux inhibition; Flow cytometry; Fluorescent substrate

Indexed keywords

CELL CULTURE; DRUG INTERACTIONS; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENT SCREENS; GLYCOPROTEINS; LASER EXCITATION; PROTEINS; SUBSTRATES;

ABCB1; ABCC1; ABCG2; BREAST CANCER RESISTANCE PROTEINS; COLLABORATIVE PROJECTS; DRUG-DRUG INTERACTIONS; FLUORESCENCE DETECTION; FLUORESCENT COMPOUNDS;

ION EXCHANGE;

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; FLUORESCENT DYE; GLIBENCLAMIDE; LOXAPINE; MOMETASONE FUROATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NICARDIPINE; NICLOSAMIDE; PIMOZIDE; RHODAMINE; VERAPAMIL; VINBLASTINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; LIPOPHILICITY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

EID: 84875919145     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2013.02.018     Document Type: Article

References (44)

1. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR, and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11 2000 265 283
2. B. Goldman Multidrug resistance: can new drugs help chemotherapy score against cancer? J. Natl Cancer Inst. 95 2003 255 257
3. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv. Drug Deliv. Rev. 55 2003 3 29
4. B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system Physiol. Rev. 86 2006 1179 1236
5. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, and G. Chang Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
6. C. Martin, G. Berridge, C.F. Higgins, P. Mistry, P. Charlton, and R. Callaghan Communication between multiple drug binding sites on P-glycoprotein Mol. Pharmacol. 58 2000 624 632
7. R. Clark, I.D. Kerr, and R. Callaghan Multiple drug-binding sites on the R482G isoform of the ABCG2 transporter Br. J. Pharmacol. 149 2006 506 515
8. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug Deliv. Rev. 55 2003 53 81
9. C.M.F. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, R.C. Jewell, E.M. Paul, and J.H.M. Schellens Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J. Clin. Oncol. 20 2002 2943 2950
10. C.Q. Xia, M.N. Milton, and L.-S. Gan Evaluation of drug-transporter interactions using in vitro and in vivo models Curr. Drug Metab. 8 2007 341 363
11. F.J. Sharom The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160 1997 161 175
12. I. Ivnitski-Steele, R.S. Larson, D.M. Lovato, H.M. Khawaja, S.S. Winter, T.I. Oprea, L.A. Sklar, and B.S. Edwards High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters Assay Drug Dev. Technol. 6 2008 263 276
13. J.J. Strouse, I. Ivnitski-Steele, H.M. Khawaja, D. Perez, J. Ricci, T. Yao, W.S. Weiner, C.E. Schroeder, D.S. Simpson, B.E. Maki, K. Li, J.E. Golden, T.D. Foutz, A. Waller, A.M. Evangelisti, S.M. Young, S.E. Chavez, M.J. Garcia, O. Ursu, C.G. Bologa, M.B. Carter, V.M. Salas, K. Gouveia, G.P. Tegos, T.I. Oprea, B.S. Edwards, J. Aubé, R.S. Larson, and L.A. Sklar A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry J. Biomol. Screen. 18 2013 26 38
14. F.W. Kuckuck, B.S. Edwards, and L.A. Sklar High throughput flow cytometry Cytometry 44 2001 83 90
15. S. Ramirez, C.T. Aiken, B. Andrzejewski, L.A. Sklar, and B.S. Edwards High-throughput flow cytometry: validation in microvolume bioassays Cytometry 53 2003 55 65
16. S.S. Winter, Z. Jiang, H.M. Khawaja, T. Griffin, M. Devidas, B.L. Asselin, and R.S. Larson Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group Blood 110 2007 1429 1438
17. P.D.W. Eckford, and F.J. Sharom ABC efflux pump-based resistance to chemotherapy drugs Chem. Rev. 109 2009 2989 3011
18. K. Shiozawa, M. Oka, H. Soda, M. Yoshikawa, Y. Ikegami, J. Tsurutani, K. Nakatomi, Y. Nakamura, S. Doi, T. Kitazaki, Y. Mizuta, K. Murase, H. Yoshida, D.R. Douglas, and S. Kohno Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic Int. J. Cancer 108 2004 146 151
19. A.M. Calcagno, I.-W. Kim, C.-P. Wu, S. Shukla, and S.V. Ambudkar ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions Curr. Drug Deliv. 4 2007 324 333
20. I.V. Lebedeva, P. Pande, and W.F. Patton Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters PLoS One 6 2011 e22429
21. E.-J. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors Biochem. Biophys. Res. Commun. 289 2001 580 585
22. T. Efferth, H. Lohrke, and M. Volm Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors Anticancer Res. 9 1989 1633 1637
23. C.J. Henrich, R.W. Robey, K. Takada, H.R. Bokesch, S.E. Bates, S. Shukla, S.V. Ambudkar, J.B. McMahon, and K.R. Gustafson Botryllamides: natural product inhibitors of ABCG2 ACS Chem. Biol. 4 2009 637 647
24. P.E. Golstein, A. Boom, J. van Geffel, P. Jacobs, B. Masereel, and R. Beauwens P-glycoprotein inhibition by glibenclamide and related compounds Pfluegers Arch. 437 1999 652 660
25. R.F. Ozols, R.E. Cunnion, R.W. Klecker Jr., T.C. Hamilton, Y. Ostchega, J.E. Parrillo, and R.C. Young Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients J. Clin. Oncol. 5 1987 641 647
26. E. Crivellato, L. Candussio, A.M. Rosati, F. Bartoli-Klugmann, F. Mallardi, and G. Decorti The fluorescent probe Bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance-related protein (MRP)-1 J. Histochem. Cytochem. 50 2002 731 734
27. A. Rosati, L. Candussio, E. Crivellato, F.B. Klugmann, T. Giraldi, D. Damiani, A. Michelutti, and G. Decorti Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins Cell Oncol. 26 2004 3 11
28. C. Avendano, and J.C. Menendez Inhibitors of multidrug resistance to antitumor agents (MDR) Curr. Med. Chem. 9 2002 159 193
29. J.M. Kuhnel, J.Y. Perrot, A.M. Faussat, J.P. Marie, and M.A. Schwaller Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe Leukemia 11 1997 1147 1155
30. M.R. Lugo, and F.J. Sharom Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site Biochemistry 44 2005 643 655
31. A.B. Shapiro, and V. Ling Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein Eur. J. Biochem. 254 1998 181 188
32. G. Szakacs, A. Varadi, C. Ozvegy-Laczka, and B. Sarkadi The role of ABC transporters in drug absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) Drug Discov. Today 13 2008 379 393
33. Y.C. Mayur, G.J. Peters, V.V. Prasad, C. Lemo, and N.K. Sathish Design of new drug molecules to be used in reversing multidrug resistance in cancer cells Curr. Cancer Drug Targets 9 2009 298 306
34. A. Seelig, and E. Gatlik-Landwojtowicz Inhibitors of multidrug efflux transporters: their membrane and protein interactions Mini-Rev. Med. Chem. 5 2005 135 151
35. L. Gandhi, M.W. Harding, M. Neubauer, C.J. Langer, M. Moore, H.J. Ross, B.E. Johnson, and T.J. Lynch A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer Cancer 109 2007 924 932
36. J.D. Allen, S.C. Jackson, and A.H. Schinkel A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance Cancer Res. 62 2002 2294 2299
37. H. Mitomo, R. Kato, A. Ito, S. Kasamatsu, Y. Ikegami, I. Kii, A. Kudo, E. Kobatake, Y. Sumino, and T. Ishikawa A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport Biochem. J. 373 2003 767 774
38. C. Ozvegy-Laczka, G. Koblos, B. Sarkadi, and A. Varadi Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition Biochim. Biophys. Acta 1668 2005 53 63
39. C. Coburger, H. Lage, J. Molnar, and A. Hilgeroth Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies Pharm. Res. 26 2009 182 188
40. A.B. Shapiro, and V. Ling Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities Eur. J. Biochem. 250 1997 130 137
41. M.R. Lugo, and F.J. Sharom Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs Biochemistry 44 2005 14020 14029
42. 3H] vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells Eur. J. Pharmacol. 288 1994 105 114
43. R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry, and S.E. Bates Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res. 64 2004 1242 1246
44. C.J. Henrich, R.W. Robey, H.R. Bokesch, S.E. Bates, S. Shukla, S.V. Ambudkar, M. Dean, and J.B. McMahon New inhibitors of ABCG2 identified by high-throughput screening Mol. Cancer Ther. 6 2007 3271 3278